Yuewei Medical Secures Tens of Millions in Series A++ Funding to Advance Heart Failure and Coronary Artery Disease Innovations
Yellwin
Cardiac Surgery Implantable Medical Device R&D Provider
Heart Future
Recently,Yellwin(hereinafter referred to as "Yellwin"") announced the completion of an exclusive investment by the Beijing Medical and Health Industry Investment Fund.Tens of Millions of Yuan in A++ Round Financing。
This round of financing will be mainly used for two major directions: one isDeepening the innovation of the full-process devices for coronary heart disease diagnosis and treatment, and the development of new products such as pulsatile left ventricular assist systems.; Second,Accelerate the market promotion of approved products such as cardiac stabilizers。
Through this round of financing, Yellwin will comprehensively strengthen its R&D innovation and market penetration capabilities in the cardiovascular field, continuously consolidating its leading position in technology.
The company focuses on the innovation product development and transformation of medical devices and equipment solutions for the entire process of cardiac surgery. The series of products includeCoronary Artery Bypass Grafting (CABG) Heart Stabilizer, Intraoperative Ultrasound Flow Detector, Left Ventricular Assist Device, Coronary Anastomosis Assistance SystemA series of pioneering achievements exclusively created in China.
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Core Project ApplicationMore than 20 national invention patents, the new generation of heart stabilizers, femoral arteriovenous extracorporeal circulation catheters, and coronary heart disease scoring systems developed have completed the research and development phase and entered the registration certificate application stage.
YellwinFounded in 2021,Initiated by a team of cardiac surgery experts with over 20 years of clinical experience from Beijing Anzhen Hospital, Capital Medical University, Yellwin is an innovative enterprise focused on the development of devices in the field of cardiac surgery and heart failure.
Yellwin's products coverCardiac Stabilizer, Vascular Anastomosis Quality Control System, Coronary Heart Disease Scoring System, Pulsatile Left Ventricular Assist System, and Coronary Artery Bypass Quality Control Systemetc. The company owns more than 50 patents domestically and internationally. Its R&D team is composed of interdisciplinary talents with backgrounds in clinical medicine, medical device hardware, and AI algorithms, possessing strong technical capabilities. The company adopts a "moderately forward-looking R&D + gradient commercial transformation" strategy and has received numerous honors as a national high-tech enterprise and a specialized, refined, unique, and innovative enterprise.
2021:Angel Round Financing
2023: ByJointly invested by IDG Capital and Yuanhui ChuangyiTens of Millions of Yuan in Series A Financing
2023: Jointly invested by Noyou Capital, Zhongnan Venture Capital, Qichen Holdings, IDG Capital, and Yuanhui ChuangyiNearly 100 Million Yuan in A+ Round Financing